Treatment | RWPE-1% survival | FR generated % of control | LXA4levels % of control | IL-6% of control | TNF-α % of control |
---|---|---|---|---|---|
Control | 100 ± 3.49 | 100 ± 5.40 | 100 ± 0.43 | 100 ± 0.74 | 100 ± 6.43 |
LA 50 μM | 94.74 ± 7.01* | 104.61 ± 10.00* | 48.75 ± 10.46*** | 86.96 ± 11.94** | 165.71 ± 8.60*** |
LA 150 μM | 73.68 ± 3.58** | 84.00 ± 7.38** | 67.96 ± 4.53** | 82.12 ± 11.94** | 114.28 ± 10.77** |
GLA 25 μM | 98.39 ± 2.94* | 50.66 ± 4.80*** | 49.91 ± 0.70*** | 18.70 ± 0.42*** | 57.03 ± 7.18*** |
GLA 50 μM | 108.64 ± 7.30* | 64.14 ± 5.10*** | 71.43 ± 0.79** | 31.32 ± 0.51*** | 53.91 ± 7.47*** |
GLA 75 μM | 85.25 ± 4.95** | 78.71 ± 2.77** | 80.65 ± 2.17** | 42.92 ± 1.17*** | 89.01 ± 0.97** |
AA 50 μM | 106.46 ± 0.69* | 71.89 ± 2.17** | 60.18 ± 0.79*** | 99.42 ± 0.30 | 66.16 ± 0.94** |
AA 100 μM | 41.92 ± 3.93*** | 69.03 ± 5.77** | 179.05 ± 1.95*** | 99.78 ± 0.23 | 64.73 ± 1.83** |
ALA 50 μM | 90.91 ± 7.35* | 80.00 ± 7.34** | 37.04 ± 6.00*** | 114.28 ± 7.49* | 178.57 ± 2.85*** |
ALA150μM | 59.09 ± 5.44** | 100.23 ± 8.08 | 70.37 ± 6.00** | 130.95 ± 6.43** | 149.28 ± 5.77** |
EPA 50 μM | 108.2 ± 7.74* | 60.60 ± 6.50*** | 67.00 ± 1.15** | 97.30 ± 0.57 | 47.69 ± 3.03*** |
EPA 100 μM | 82.61 ± 7.85** | 39.47 ± 4.32*** | 41.69 ± 0.64*** | 102.22 ± 0.93 | 35.47 ± 6.16*** |
DHA 50 μM | 96.47 ± 9.31* | 75.69 ± 5.70** | 46.42 ± 1.06*** | 99.60 ± 0.44 | 44.74 ± 3.31*** |
DHA100μM | 85.71 ± 3.97** | 74.74 ± 6.44** | 51.95 ± 1.69*** | 111.70 ± 2.09* | 54.73 ± 5.25*** |